CDK7


Also found in: Acronyms.

CDK7

A gene on chromosome 5q12.1 that encodes a cyclin-dependent kinase, an important regulator of cell cycle progression. CDK7 forms a trimeric complex with cyclin H and MAT1 and is a key component of the transcription factor TFIIH, which is involved in transcription initiation and DNA repair.
References in periodicals archive ?
Moreover, we showed that the cell-cycle arrest was accompanied by down-regulation of CCNA1, CCND1, CCND2, CCNH, CDKN1B, MCM2, ORC6L, and WEE1 and upregulation of CDC7, CDK6, CDK7, E2F3, and RB1.
Toona Sinensis and Moschus decoction induced cell cycle arrest in human cervical carcinoma HeLa cells
Abbreviations: ARG, arctigenin; GSH, glutathione; [G.sub.0]/[G.sub.1] , Gap 0/Gap 1; NPAT, nuclear protein of the ataxia telangiectasia locus; CDK2, cyclin-dependent kinase 2; CDK7, cyclin-dependent kinase 7: akt-1, alpha serine/threonine-protein kinase.
CDK7, cyclin-dependent kinase 7; akt-1, alpha serine/threonine-protein kin
Mechanism of arctigenin-mediated specific cytotoxicity against human lung adenocarcinoma cell lines
New preclinical data on SY-5609, a selective oral CDK7 inhibitor, demonstrate broad anti-tumor activity in preclinical models of triple-negative breast cancer and ovarian cancer.
Demonstrated 13,000- to 49,000-fold greater selectivity for CDK7 over other CDK family members, including CDK2, CDK9 and CDK12.
Syros Presents New Preclinical Data on SY-1365 and SY-5609 at AACR Annual Meeting
agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor in a Phase 1 clinical trial for patients with ovarian and breast cancers.
Syros Releases New Preclinical Data on SY-1365 at San Antonio Breast Cancer Symposium
PD assays used to establish proof-of-mechanism included a CDK7 occupancy assay to evaluate SY-1365 binding and a custom gene expression assay to evaluate downstream transcriptional changes in patients.
Syros Releases Dose Escalation Data from Phase 1 Trial of SY-1365 Demonstrating Proof-of-Mechanism at Tolerable Doses in Patients with Advanced Solid Tumors
M2 PHARMA-May 16, 2017-First Patient Dosed in Phase 1 Clinical Trial of Syros' SY-1365 Selective CDK7 Inhibitor in Patients with Advanced Solid Tumors
First Patient Dosed in Phase 1 Clinical Trial of Syros' SY-1365 Selective CDK7 Inhibitor in Patients with Advanced Solid Tumors
M2 PHARMA-April 11, 2017-US FDA Accepts Syros IND to Advance Its SY-1365 Selective CDK7 Inhibitor into Phase 1 Clinical Trial
US FDA Accepts Syros IND to Advance Its SY-1365 Selective CDK7 Inhibitor into Phase 1 Clinical Trial
Medical browser ?
Full browser ?